NCT06540963View on ClinicalTrials.gov

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2035

Conditions
Neuroblastoma Recurrent
Interventions
DRUG

Tipifarnib

Tablet

DRUG

Naxitamab

IV

Trial Locations (3)

17033

RECRUITING

Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey

72202

RECRUITING

Arkansas Children's Hospital, Little Rock

97227

RECRUITING

Randall Children's Hospital, Portland

All Listed Sponsors
lead

Giselle Sholler

OTHER